Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Improving Global Access to Genomic Profiling in Rare Pediatric Cancers.
Farouk Sait S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Mechanisms of resistance to RET-directed therapies.
Clifton-Bligh RJ
Endocrine-related Cancer, 2025
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W et al.
International Journal of Molecular Medicine, 2025
RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting.
Wallen ZD et al.
Frontiers in Genetics, 2025
A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma.
Li H et al.
Current Oncology (toronto, Ont.), 2024
ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models.
Schmid S et al.
Cell Reports, 2024
BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors.
Sheng J et al.
Npj Precision Oncology, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Roa P et al.
British Journal of Cancer, 2024
Liquid Biopsy Profiling with Multiple Tests in Patients with Metastatic Breast Cancer.
Higa N et al.
Journal of Molecular Pathology, 2024
Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms.
Cowzer D et al.
Endocrine-related Cancer, 2024
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
Subbiah V et al.
Npj Precision Oncology, 2024
Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A et al.
Biomarker Research, 2024
Critical domains for NACC2-NTRK2 fusion protein activation.
Yang W et al.
Plos One, 2024
China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
Qi C et al.
International Journal of Cancer, 2023
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Ghelani GH et al.
Urologic Oncology, 2023
Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China.
Xu Y et al.
Npj Precision Oncology, 2023
Actionability classification of variants of unknown significance correlates with functional effect.
Johnson A et al.
Npj Precision Oncology, 2023
Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.
Boyarskikh UA et al.
Bulletin of Experimental Biology and Medicine, 2023
Progressive metastatic infantile fibrosarcoma with multiple acquired mutations.
Furtado LV et al.
Cold Spring Harbor Molecular Case Studies, 2023
Kinase inhibitors in thyroid cancers.
Sukrithan V et al.
Endocrine Oncology (bristol, England), 2023
Targeting Gatekeeper Mutations for Kinase Drug Discovery.
Zhou Y et al.
Journal of Medicinal Chemistry, 2022
Kinase Fusion-Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics.
Chu YH et al.
Endocrine Pathology, 2022
JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Wang J et al.
Molecules (basel, Switzerland), 2022
Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations.
Wang ZZ et al.
Briefings in Bioinformatics, 2022
Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase.
Mei LC et al.
European Journal of Medicinal Chemistry, 2022
Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang Z et al.
Journal of Medicinal Chemistry, 2022
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
Chakravarty D et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2022
Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.
Nguyen HT et al.
Frontiers in Oncology, 2022
DeteX: A highly accurate software for detecting SNV and InDel in single and paired NGS data in cancer research.
Cui Y et al.
Frontiers in Genetics, 2022
Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
Wu WC et al.
Frontiers in Oncology, 2022
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Murray BW et al.
Molecular Cancer Therapeutics, 2021
Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.
Zhuo LS et al.
Journal of Medicinal Chemistry, 2021
Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
Keddy C et al.
Cold Spring Harbor Molecular Case Studies, 2021
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature.
Gupta M et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2021
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.
Grunewald S et al.
Cancer Discovery, 2021
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Cocco E et al.
Cancer Discovery, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R et al.
Communications Biology, 2020
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)].
Unknown Author
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2020
Genomic Alteration in Metastatic Breast Cancer and Its Treatment.
Li A et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 2020
Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer.
Jin W
Cancers, 2020
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.
Chu QS
Therapeutic Advances in Medical Oncology, 2020
RET kinase alterations in targeted cancer therapy.
Liu X et al.
Cancer Drug Resistance (alhambra, Calif.), 2020
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Terzyan SS et al.
The Journal of Biological Chemistry, 2019
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW et al.
The Lancet. Oncology, 2018